

# Global Respiratory Syncytial Virus Vaccine for the Elderly Market Growth 2026-2032

<https://marketpublishers.com/r/G9651444E565EN.html>

Date: February 2026

Pages: 121

Price: US\$ 3,660.00 (Single User License)

ID: G9651444E565EN

## Abstracts

The global Respiratory Syncytial Virus Vaccine for the Elderly market size is predicted to grow from US\$ million in 2025 to US\$ million in 2032; it is expected to grow at a CAGR of % from 2026 to 2032.

United States market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

China market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Europe market for Respiratory Syncytial Virus Vaccine for the Elderly is estimated to increase from US\$ million in 2025 to US\$ million by 2032, at a CAGR of % from 2026 through 2032.

Global key Respiratory Syncytial Virus Vaccine for the Elderly players cover GSK, Pfizer, Moderna, Daiichi Sankyo, Icosavax, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2025.

LP Information, Inc. (LPI) ' newest research report, the "Respiratory Syncytial Virus Vaccine for the Elderly Industry Forecast" looks at past sales and reviews total world Respiratory Syncytial Virus Vaccine for the Elderly sales in 2025, providing a comprehensive analysis by region and market sector of projected Respiratory Syncytial Virus Vaccine for the Elderly sales for 2026 through 2032. With Respiratory Syncytial Virus Vaccine for the Elderly sales broken down by region, market sector and sub-

sector, this report provides a detailed analysis in US\$ millions of the world Respiratory Syncytial Virus Vaccine for the Elderly industry.

This Insight Report provides a comprehensive analysis of the global Respiratory Syncytial Virus Vaccine for the Elderly landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Respiratory Syncytial Virus Vaccine for the Elderly portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Respiratory Syncytial Virus Vaccine for the Elderly market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Respiratory Syncytial Virus Vaccine for the Elderly and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Respiratory Syncytial Virus Vaccine for the Elderly.

This report presents a comprehensive overview, market shares, and growth opportunities of Respiratory Syncytial Virus Vaccine for the Elderly market by product type, application, key manufacturers and key regions and countries.

### **Segmentation by Type:**

Recombinant Protein Vaccine

Nucleic Acid Vaccines

Others

### **Segmentation by Application:**

Hospital

Centers for Disease Control and Prevention

Others

**This report also splits the market by region:**

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.

GSK

Pfizer

Moderna

Daiichi Sankyo

Icosavax

Sanofi

Blue Lake Biotechnology

Advaccine

Starna Therapeutics

Immorna

Clover Biopharma

Innorna

RNAimmune

### **Key Questions Addressed in this Report**

What is the 10-year outlook for the global Respiratory Syncytial Virus Vaccine for the Elderly market?

What factors are driving Respiratory Syncytial Virus Vaccine for the Elderly market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Respiratory Syncytial Virus Vaccine for the Elderly market opportunities vary by end market size?

How does Respiratory Syncytial Virus Vaccine for the Elderly break out by Type, by Application?

## Contents

### 1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

### 2 EXECUTIVE SUMMARY

#### 2.1 World Market Overview

2.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales 2021-2032

2.1.2 World Current & Future Analysis for Respiratory Syncytial Virus Vaccine for the Elderly by Geographic Region, 2021, 2025 & 2032

2.1.3 World Current & Future Analysis for Respiratory Syncytial Virus Vaccine for the Elderly by Country/Region, 2021, 2025 & 2032

#### 2.2 Respiratory Syncytial Virus Vaccine for the Elderly Segment by Type

2.2.1 Recombinant Protein Vaccine

2.2.2 Nucleic Acid Vaccines

2.2.3 Others

2.2.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type

2.2.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)

2.2.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue and Market Share by Type (2021-2026)

2.2.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Type (2021-2026)

#### 2.3 Respiratory Syncytial Virus Vaccine for the Elderly Segment by Application

2.3.1 Hospital

2.3.2 Centers for Disease Control and Prevention

2.3.3 Others

2.3.4 Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application

2.3.4.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share

by Application (2021-2026)

2.3.4.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue and Market Share by Application (2021-2026)

2.3.4.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Application (2021-2026)

### **3 GLOBAL BY COMPANY**

3.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Breakdown Data by Company

3.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Company (2021-2026)

3.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company (2021-2026)

3.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Company (2021-2026)

3.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2021-2026)

3.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company (2021-2026)

3.3 Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Company

3.4 Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Product Location Distribution

3.4.2 Players Respiratory Syncytial Virus Vaccine for the Elderly Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

3.6 New Products and Potential Entrants

3.7 Market M&A Activity & Strategy

### **4 WORLD HISTORIC REVIEW FOR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY BY GEOGRAPHIC REGION**

4.1 World Historic Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Geographic Region (2021-2026)

4.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Geographic Region (2021-2026)

4.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Geographic Region (2021-2026)

4.2 World Historic Respiratory Syncytial Virus Vaccine for the Elderly Market Size by Country/Region (2021-2026)

4.2.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales by Country/Region (2021-2026)

4.2.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue by Country/Region (2021-2026)

4.3 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth

4.4 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth

4.5 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth

4.6 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth

## **5 AMERICAS**

5.1 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country

5.1.1 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)

5.1.2 Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)

5.2 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)

5.3 Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

## **6 APAC**

6.1 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region

6.1.1 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026)

6.1.2 APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026)

6.2 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)

6.3 APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

## **7 EUROPE**

7.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly by Country

7.1.1 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)

7.1.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)

7.2 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)

7.3 Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

## **8 MIDDLE EAST & AFRICA**

8.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly by Country

8.1.1 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026)

8.1.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026)

8.2 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026)

8.3 Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026)

8.4 Egypt

- 8.5 South Africa
- 8.6 Israel
- 8.7 Turkey
- 8.8 GCC Countries

## **9 MARKET DRIVERS, CHALLENGES AND TRENDS**

- 9.1 Market Drivers & Growth Opportunities
- 9.2 Market Challenges & Risks
- 9.3 Industry Trends

## **10 MANUFACTURING COST STRUCTURE ANALYSIS**

- 10.1 Raw Material and Suppliers
- 10.2 Manufacturing Cost Structure Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
- 10.3 Manufacturing Process Analysis of Respiratory Syncytial Virus Vaccine for the Elderly
- 10.4 Industry Chain Structure of Respiratory Syncytial Virus Vaccine for the Elderly

## **11 MARKETING, DISTRIBUTORS AND CUSTOMER**

- 11.1 Sales Channel
  - 11.1.1 Direct Channels
  - 11.1.2 Indirect Channels
- 11.2 Respiratory Syncytial Virus Vaccine for the Elderly Distributors
- 11.3 Respiratory Syncytial Virus Vaccine for the Elderly Customer

## **12 WORLD FORECAST REVIEW FOR RESPIRATORY SYNCYTIAL VIRUS VACCINE FOR THE ELDERLY BY GEOGRAPHIC REGION**

- 12.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Market Size Forecast by Region
  - 12.1.1 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Region (2027-2032)
  - 12.1.2 Global Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Region (2027-2032)
- 12.2 Americas Forecast by Country (2027-2032)
- 12.3 APAC Forecast by Region (2027-2032)

12.4 Europe Forecast by Country (2027-2032)

12.5 Middle East & Africa Forecast by Country (2027-2032)

12.6 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Type (2027-2032)

12.7 Global Respiratory Syncytial Virus Vaccine for the Elderly Forecast by Application (2027-2032)

## **13 KEY PLAYERS ANALYSIS**

### **13.1 GSK**

13.1.1 GSK Company Information

13.1.2 GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

13.1.3 GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

13.1.4 GSK Main Business Overview

13.1.5 GSK Latest Developments

### **13.2 Pfizer**

13.2.1 Pfizer Company Information

13.2.2 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

13.2.3 Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

13.2.4 Pfizer Main Business Overview

13.2.5 Pfizer Latest Developments

### **13.3 Moderna**

13.3.1 Moderna Company Information

13.3.2 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

13.3.3 Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

13.3.4 Moderna Main Business Overview

13.3.5 Moderna Latest Developments

### **13.4 Daiichi Sankyo**

13.4.1 Daiichi Sankyo Company Information

13.4.2 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

13.4.3 Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

- 13.4.4 Daiichi Sankyo Main Business Overview
- 13.4.5 Daiichi Sankyo Latest Developments
- 13.5 Icosavax
  - 13.5.1 Icosavax Company Information
  - 13.5.2 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
  - 13.5.3 Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.5.4 Icosavax Main Business Overview
  - 13.5.5 Icosavax Latest Developments
- 13.6 Sanofi
  - 13.6.1 Sanofi Company Information
  - 13.6.2 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
  - 13.6.3 Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.6.4 Sanofi Main Business Overview
  - 13.6.5 Sanofi Latest Developments
- 13.7 Blue Lake Biotechnology
  - 13.7.1 Blue Lake Biotechnology Company Information
  - 13.7.2 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
  - 13.7.3 Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.7.4 Blue Lake Biotechnology Main Business Overview
  - 13.7.5 Blue Lake Biotechnology Latest Developments
- 13.8 Advaccine
  - 13.8.1 Advaccine Company Information
  - 13.8.2 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
  - 13.8.3 Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)
  - 13.8.4 Advaccine Main Business Overview
  - 13.8.5 Advaccine Latest Developments
- 13.9 Starna Therapeutics
  - 13.9.1 Starna Therapeutics Company Information
  - 13.9.2 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications
  - 13.9.3 Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales,

## Revenue, Price and Gross Margin (2021-2026)

### 13.9.4 Starna Therapeutics Main Business Overview

### 13.9.5 Starna Therapeutics Latest Developments

## 13.10 Immorna

### 13.10.1 Immorna Company Information

### 13.10.2 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

### 13.10.3 Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

### 13.10.4 Immorna Main Business Overview

### 13.10.5 Immorna Latest Developments

## 13.11 Clover Biopharma

### 13.11.1 Clover Biopharma Company Information

### 13.11.2 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

### 13.11.3 Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

### 13.11.4 Clover Biopharma Main Business Overview

### 13.11.5 Clover Biopharma Latest Developments

## 13.12 Innorna

### 13.12.1 Innorna Company Information

### 13.12.2 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

### 13.12.3 Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

### 13.12.4 Innorna Main Business Overview

### 13.12.5 Innorna Latest Developments

## 13.13 RNAimmune

### 13.13.1 RNAimmune Company Information

### 13.13.2 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

### 13.13.3 RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales, Revenue, Price and Gross Margin (2021-2026)

### 13.13.4 RNAimmune Main Business Overview

### 13.13.5 RNAimmune Latest Developments

## **14 RESEARCH FINDINGS AND CONCLUSION**

## List Of Tables

### LIST OF TABLES

Table 1. Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales CAGR by Geographic Region (2021, 2025 & 2032) & (\$ millions)

Table 2. Respiratory Syncytial Virus Vaccine for the Elderly Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & (\$ millions)

Table 3. Major Players of Recombinant Protein Vaccine

Table 4. Major Players of Nucleic Acid Vaccines

Table 5. Major Players of Others

Table 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)

Table 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)

Table 8. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Type (2021-2026) & (\$ million)

Table 9. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026)

Table 10. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Type (2021-2026) & (US\$/Dose)

Table 11. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale by Application (2021-2026) & (Dose)

Table 12. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2021-2026)

Table 13. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Application (2021-2026) & (\$ million)

Table 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Application (2021-2026)

Table 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Application (2021-2026) & (US\$/Dose)

Table 16. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Company (2021-2026) & (Dose)

Table 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company (2021-2026)

Table 18. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company (2021-2026) & (\$ millions)

Table 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company (2021-2026)

Table 20. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Price by Company (2021-2026) & (US\$/Dose)

Table 21. Key Manufacturers Respiratory Syncytial Virus Vaccine for the Elderly Producing Area Distribution and Sales Area

Table 22. Players Respiratory Syncytial Virus Vaccine for the Elderly Products Offered

Table 23. Respiratory Syncytial Virus Vaccine for the Elderly Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)

Table 24. New Products and Potential Entrants

Table 25. Market M&A Activity & Strategy

Table 26. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Region (2021-2026) & (Dose)

Table 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Geographic Region (2021-2026)

Table 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Geographic Region (2021-2026) & (\$ millions)

Table 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Geographic Region (2021-2026)

Table 30. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country/Region (2021-2026) & (Dose)

Table 31. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2021-2026)

Table 32. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country/Region (2021-2026) & (\$ millions)

Table 33. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country/Region (2021-2026)

Table 34. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)

Table 35. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026)

Table 36. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & (\$ millions)

Table 37. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)

Table 38. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)

Table 39. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Region (2021-2026) & (Dose)

Table 40. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region (2021-2026)

- Table 41. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Region (2021-2026) & (\$ millions)
- Table 42. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
- Table 43. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
- Table 44. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
- Table 45. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Country (2021-2026) & (\$ millions)
- Table 46. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
- Table 47. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
- Table 48. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Country (2021-2026) & (Dose)
- Table 49. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)
- Table 50. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Type (2021-2026) & (Dose)
- Table 51. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales by Application (2021-2026) & (Dose)
- Table 52. Key Market Drivers & Growth Opportunities of Respiratory Syncytial Virus Vaccine for the Elderly
- Table 53. Key Market Challenges & Risks of Respiratory Syncytial Virus Vaccine for the Elderly
- Table 54. Key Industry Trends of Respiratory Syncytial Virus Vaccine for the Elderly
- Table 55. Respiratory Syncytial Virus Vaccine for the Elderly Raw Material
- Table 56. Key Suppliers of Raw Materials
- Table 57. Respiratory Syncytial Virus Vaccine for the Elderly Distributors List
- Table 58. Respiratory Syncytial Virus Vaccine for the Elderly Customer List
- Table 59. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Region (2027-2032) & (Dose)
- Table 60. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Region (2027-2032) & (\$ millions)
- Table 61. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)
- Table 62. Americas Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 63. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Region (2027-2032) & (Dose)

Table 64. APAC Respiratory Syncytial Virus Vaccine for the Elderly Annual Revenue Forecast by Region (2027-2032) & (\$ millions)

Table 65. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)

Table 66. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 67. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Country (2027-2032) & (Dose)

Table 68. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Country (2027-2032) & (\$ millions)

Table 69. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Type (2027-2032) & (Dose)

Table 70. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Type (2027-2032) & (\$ millions)

Table 71. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Forecast by Application (2027-2032) & (Dose)

Table 72. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Forecast by Application (2027-2032) & (\$ millions)

Table 73. GSK Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 74. GSK Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 75. GSK Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 76. GSK Main Business

Table 77. GSK Latest Developments

Table 78. Pfizer Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 79. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 80. Pfizer Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 81. Pfizer Main Business

Table 82. Pfizer Latest Developments

Table 83. Moderna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 84. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Product

## Portfolios and Specifications

Table 85. Moderna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 86. Moderna Main Business

Table 87. Moderna Latest Developments

Table 88. Daiichi Sankyo Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 89. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 90. Daiichi Sankyo Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 91. Daiichi Sankyo Main Business

Table 92. Daiichi Sankyo Latest Developments

Table 93. Icosavax Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 94. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 95. Icosavax Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 96. Icosavax Main Business

Table 97. Icosavax Latest Developments

Table 98. Sanofi Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 99. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 100. Sanofi Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 101. Sanofi Main Business

Table 102. Sanofi Latest Developments

Table 103. Blue Lake Biotechnology Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 104. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 105. Blue Lake Biotechnology Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 106. Blue Lake Biotechnology Main Business

Table 107. Blue Lake Biotechnology Latest Developments

Table 108. Advaccine Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 109. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 110. Advaccine Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 111. Advaccine Main Business

Table 112. Advaccine Latest Developments

Table 113. Starna Therapeutics Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 114. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 115. Starna Therapeutics Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 116. Starna Therapeutics Main Business

Table 117. Starna Therapeutics Latest Developments

Table 118. Immorna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 119. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 120. Immorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 121. Immorna Main Business

Table 122. Immorna Latest Developments

Table 123. Clover Biopharma Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 124. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 125. Clover Biopharma Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 126. Clover Biopharma Main Business

Table 127. Clover Biopharma Latest Developments

Table 128. Innorna Basic Information, Respiratory Syncytial Virus Vaccine for the Elderly Manufacturing Base, Sales Area and Its Competitors

Table 129. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 130. Innorna Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 131. Innorna Main Business

Table 132. Innorna Latest Developments

Table 133. RNAimmune Basic Information, Respiratory Syncytial Virus Vaccine for the

Elderly Manufacturing Base, Sales Area and Its Competitors

Table 134. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Product Portfolios and Specifications

Table 135. RNAimmune Respiratory Syncytial Virus Vaccine for the Elderly Sales (Dose), Revenue (\$ Million), Price (US\$/Dose) and Gross Margin (2021-2026)

Table 136. RNAimmune Main Business

Table 137. RNAimmune Latest Developments

## List Of Figures

### LIST OF FIGURES

- Figure 1. Picture of Respiratory Syncytial Virus Vaccine for the Elderly
- Figure 2. Respiratory Syncytial Virus Vaccine for the Elderly Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Growth Rate 2021-2032 (Dose)
- Figure 7. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth Rate 2021-2032 (\$ millions)
- Figure 8. Respiratory Syncytial Virus Vaccine for the Elderly Sales by Geographic Region (2021, 2025 & 2032) & (\$ millions)
- Figure 9. Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2025)
- Figure 10. Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country/Region (2021, 2025 & 2032)
- Figure 11. Product Picture of Recombinant Protein Vaccine
- Figure 12. Product Picture of Nucleic Acid Vaccines
- Figure 13. Product Picture of Others
- Figure 14. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type in 2026
- Figure 15. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Type (2021-2026)
- Figure 16. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Hospital
- Figure 17. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Hospital (2021-2026) & (Dose)
- Figure 18. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Centers for Disease Control and Prevention
- Figure 19. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Centers for Disease Control and Prevention (2021-2026) & (Dose)
- Figure 20. Respiratory Syncytial Virus Vaccine for the Elderly Consumed in Others
- Figure 21. Global Respiratory Syncytial Virus Vaccine for the Elderly Market: Others (2021-2026) & (Dose)
- Figure 22. Global Respiratory Syncytial Virus Vaccine for the Elderly Sale Market Share by Application (2025)
- Figure 23. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market

Share by Application in 2026

Figure 24. Respiratory Syncytial Virus Vaccine for the Elderly Sales by Company in 2026 (Dose)

Figure 25. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Company in 2026

Figure 26. Respiratory Syncytial Virus Vaccine for the Elderly Revenue by Company in 2026 (\$ millions)

Figure 27. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Company in 2026

Figure 28. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Geographic Region (2021-2026)

Figure 29. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Geographic Region in 2026

Figure 30. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)

Figure 31. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 (\$ millions)

Figure 32. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)

Figure 33. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 (\$ millions)

Figure 34. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)

Figure 35. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 (\$ millions)

Figure 36. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales 2021-2026 (Dose)

Figure 37. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue 2021-2026 (\$ millions)

Figure 38. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country in 2026

Figure 39. Americas Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)

Figure 40. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)

Figure 41. Americas Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)

Figure 42. United States Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 43. Canada Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 44. Mexico Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 45. Brazil Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 46. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Region in 2026

Figure 47. APAC Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Region (2021-2026)

Figure 48. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)

Figure 49. APAC Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)

Figure 50. China Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 51. Japan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 52. South Korea Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 53. Southeast Asia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 54. India Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 55. Australia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 56. China Taiwan Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 57. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country in 2026

Figure 58. Europe Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share by Country (2021-2026)

Figure 59. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)

Figure 60. Europe Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)

Figure 61. Germany Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 62. France Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth

2021-2026 (\$ millions)

Figure 63. UK Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth

2021-2026 (\$ millions)

Figure 64. Italy Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth

2021-2026 (\$ millions)

Figure 65. Russia Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth

2021-2026 (\$ millions)

Figure 66. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Country (2021-2026)

Figure 67. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Type (2021-2026)

Figure 68. Middle East & Africa Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share by Application (2021-2026)

Figure 69. Egypt Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 70. South Africa Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 71. Israel Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 72. Turkey Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 73. GCC Countries Respiratory Syncytial Virus Vaccine for the Elderly Revenue Growth 2021-2026 (\$ millions)

Figure 74. Manufacturing Cost Structure Analysis of Respiratory Syncytial Virus Vaccine for the Elderly in 2026

Figure 75. Manufacturing Process Analysis of Respiratory Syncytial Virus Vaccine for the Elderly

Figure 76. Industry Chain Structure of Respiratory Syncytial Virus Vaccine for the Elderly

Figure 77. Channels of Distribution

Figure 78. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Forecast by Region (2027-2032)

Figure 79. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Region (2027-2032)

Figure 80. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market Share Forecast by Type (2027-2032)

Figure 81. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market Share Forecast by Type (2027-2032)

Figure 82. Global Respiratory Syncytial Virus Vaccine for the Elderly Sales Market

Share Forecast by Application (2027-2032)

Figure 83. Global Respiratory Syncytial Virus Vaccine for the Elderly Revenue Market

Share Forecast by Application (2027-2032)

## I would like to order

Product name: Global Respiratory Syncytial Virus Vaccine for the Elderly Market Growth 2026-2032

Product link: <https://marketpublishers.com/r/G9651444E565EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G9651444E565EN.html>